Team Building Event & Leadership Transition Announcement.
24 September 2024

We are pleased to share the success of our recent team-building event, which took place in the heart of historic Liège. The day offered a valuable opportunity for our team to strengthen their bonds and collaborate. We extend our gratitude to the entire team for their positivity and dedication throughout the day.

This occasion also marks an important leadership transition within our organization. We are delighted to introduce Damien Toulorge, our new Chief Scientific Officer(CSO). Damien brings over 15 years of expertise in neurodegenerative diseases, offering a wealth of experience and a fresh, inspiring vision for Amyl's ongoing and future projects.

Damien succeeds Karine Goraj, who has decided to pursue other professional opportunities. However, we are fortunate that Karine will continue to lend her strategic expertise to Amyl as a Strategic Advisor. We thank Karine for her outstanding leadership and commitment over the past three years, which have significantly contributed to the company’s growth and success.

We look forward to continuing our journey with Damien’s leadership and welcome him warmly to the team.

Connect
Arrow right
About Merieux Equity Partners
Mérieux Equity Partners (MxEP) is an AMF-accredited management company dedicated to  equity investments in healthcare. MxEP actively supports entrepreneurs and companies  with differentiated products and services, giving them privileged access to its sector  expertise and international network. MxEP currently manages c.€1.5bn ($1.6bn) AUM.
About Noshaq Partners
Noshaq is a Belgian investment fund and project developer with a portfolio of 477 companies. Noshaq is the reference financial partner for the creation and development of SMEs in the Liege region (Wallonia). Over the years, it has developed a range of financing vehicles in line with the needs and trends of the market and its strategy. Each service offered by Noshaq (capital – loan – leasing) is always determined according to the demands and needs of the owner-investor. Its objective is always to have a leverage effect on the company’s development.
About Sambrinvest
With over 35 years of experience working alongside companies and entrepreneurs, more than 280 portfolio companies and 170 million euros in assets under management, Sambrinvest is a major venture capital player in Wallonia. More than an investment fund, Sambrinvest is also a catalyst for the development of local ecosystems, such as biotech, digital and engineering.
3.6.21
Amyl Therapeutics closes €18.3 million